New Predictive Model Evaluates 12-Month Recurrence Risk in Non-Puerperal Mastitis
Researchers have developed and internally validated a clinical nomogram to predict the one-year recurrence risk of non-puerperal mastitis based on a retrospective cohort study of 517 patients.
Key points
- Retrospective study evaluated 517 patients across two hospitals over a 12-month period.
- Model identified white blood cell count, axillary lymphadenopathy, and surgery type as risk factors.
- Apparent AUC reached 0.921, though external validation is required prior to clinical use.
A recent study published in Nature Health Sciences details the development of a 12-month recurrence risk prediction model for non-puerperal mastitis (NPM), a challenging inflammatory breast condition. Investigators at multiple hospitals retrospectively analyzed data from 517 patients treated between January 2020 and August 2024 to identify key factors influencing disease relapse.
Using LASSO and multivariate logistic regression analyses, the researchers identified five distinct predictors of recurrence. Elevated white blood cell counts, the presence of axillary lymphadenopathy, and specific surgical procedures were highlighted as independent risk factors. Conversely, older age and an elevated monocyte proportion appeared to function as protective factors against relapse. During the 12-month observation window, 56 patients, representing 10.8% of the cohort, experienced a recurrence of symptoms.
The resulting predictive nomogram demonstrated strong statistical performance, achieving an apparent area under the curve (AUC) of 0.921 and an optimism-corrected AUC of 0.897 after rigorous bootstrap validation. However, study authors caution that the findings are currently exploratory. The association with surgical methods, for instance, reflects a predictive marker rather than direct causation, largely due to potential confounding by indication.
What to know: The nomogram offers a promising tool for estimating one-year non-puerperal mastitis recurrence, but external validation across diverse patient populations is necessary before widespread clinical implementation. Patients should consult healthcare professionals for personalized medical advice and treatment decisions regarding breast conditions.
Source Nature Health Sciences — nature.com/articles/s41598-026-79745-y ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…